Viewing data from:

CANASA

NDA

MESALAMINE | N021252 | ABBVIE INC

2 strengths2 unique patents0 unique exclusivities

Patent Timeline

2 unique patents by expiration date

Active (2)Today

2027

2028

Today

8217083

Jun. 6, 2028

8436051

Jun. 6, 2028

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

3 cases on OB patents from PACER

Case	Court	Filed	Status	Judge
Aptalis Pharma US, Inc. et al v. Delcor Asset Corporation et al 1:2015cv01210 3 patentsANDA 208362mesalamine	D. Del.	2015-12-27	Terminated 2016-04-19	—
APTALIS PHARMA US, INC. et al v. DELCOR ASSET CORPORATION et al 3:2015cv08919 3 patentsANDA 208362mesalamine	D.N.J.	2015-12-23	Terminated 2016-04-20	—
APTALIS PHARMA US INC. et al v. MYLAN PHARMACEUTICALS, INC. et al 3:2013cv04158 3 patentsmesalamine	D.N.J.	2013-07-05	Terminated 2015-11-23	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Medicare Part D Spending

CMS annual spending data for Canasa (2023)

Total Spending

$1.4M

Total Claims

813

Beneficiaries

192

Avg Cost/Unit

$40.18

Spending Trend

$15.8M(2019)→$9.7M(2020)→$2.6M(2021)→$1.7M(2022)→$1.4M(2023)

YoY Change:+2.5%

5yr CAGR:+1.5%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain24 active DMFs12 inactive

21 active API suppliers hold Drug Master Files for this ingredient.

CORDEN PHARMA BERGAMO SPAMESALAMINE

DMF 118071996

CHEMI SPAMESALAMINE USP

DMF 119511996

ERREGIERRE SPAMESALAMINE USP-EP

DMF 138831998

SYNTESE ASMESALAMINE (5-AMINOSALICYLIC ACID) DRUG SUBSTANCE

DMF 196182006

IPCA LABORATORIES LTDMESALAMINE USP (PROCESS II)

DMF 226172010

ZYDUS LIFESCIENCES LTDMESALAMINE USP

DMF 229992009

ALP PHARM BEIJING CO LTDMESALAMINE

DMF 242562010

ERREGIERRE SPAMESALAMINE USP - PH.EUR. (HIGH DENSITY)

DMF 248892011

CHEMI SPAMESALAMINE CRYSTALLIZED, USP

DMF 253852011

ZYDUS LIFESCIENCES LTDMESALAMINE USP (PROCESS-II)

DMF 279392014

CTX LIFE SCIENCES PVT LTDMESALAMINE USP

DMF 290512015

SUN PHARMACEUTICAL INDUSTRIES LTDMESALAMINE USP

DMF 295752015

DIVIS LABORATORIES LTDMESALAMINE USP

DMF 299982015

MAITHRI DRUGS PRIVATE LTDMESALAMINE USP

DMF 315702017

APITORIA PHARMA PRIVATE LTDMESALAMINE USP

DMF 339102019

ALKEM LABORATORIES LTDMESALAMINE USP

DMF 339392019

MATRIX PHARMACORP PRIVATE LTDMESALAMINE USP

DMF 343742019

AMOLI ORGANICS (A DIVISION OF UMEDICA LABORATORIES PVT LTD)MESALAMINE

DMF 347922020

OPTIMUS DRUGS PRIVATE LTDMESALAMINE

DMF 351362020

SOLARA ACTIVE PHARMA SCIENCES LTDMESALAMINE USP

DMF 357172021

ZHEJIANG HENGKANG PHARMACEUTICAL CO LTDMESALAMINE USP

DMF 373192022

DASAMI LAB PRIVATE LTDMESALAMINE USP

DMF 374132022

IOL CHEMICALS AND PHARMACEUTICALS LTDMESALAMINE USP

DMF 383382023

MSN LIFE SCIENCES PRIVATE LTDMESALAMINE USP

DMF 396702024

SUN PHARMACEUTICAL INDUSTRIES LTDInactiveMESALAMINE USP (5-AMINO SALICYLIC ACID)

DMF 164312003

SIMS SRLInactiveMESALAMINE

DMF 180542005

DR REDDYS LABORATORIES LTDInactiveMESALAMINE

DMF 183872005

IPCA LABORATORIES LTDInactiveMESALAMINE USP

DMF 192612006

CORDEN PHARMA BERGAMO SPAInactiveMESALAMINE HIGH DENSITY

DMF 199932006

LUPIN MANUFACTURING SOLUTIONS LTDInactiveMESALAMINE USP

DMF 214892008

LUPIN LTDInactiveMESALAMINE USP

DMF 215142008

SUN PHARMACEUTICAL INDUSTRIES LTDInactiveMESALAMINE USP

DMF 246642011

IPCA LABORATORIES LTDInactiveMESALAMINE USP (MZ3 PROCESS)

DMF 272452013

SIGNA SA DE CVInactiveMESALAMINE USP

DMF 296762016

WANBURY LTDInactiveMESALAMINE

DMF 318872017

BEC CHEMICALS PRIVATE LTDInactiveMESALAMINE USP

DMF 362572023

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

14 letters from Drugs@FDA

Date	Submission	Document
Oct 25, 2023	SUPPL -30	View Letter (PDF)
Nov 17, 2022	SUPPL -29	View Letter (PDF)
Nov 2, 2021	SUPPL -28	View Letter (PDF)
Oct 2, 2020	SUPPL -25	View Letter (PDF)
Aug 2, 2017	SUPPL -23	View Letter (PDF)
Sep 2, 2016	SUPPL -14	View Letter (PDF)
Dec 20, 2013	SUPPL -20	View Letter (PDF)
Feb 7, 2013	SUPPL -13	View Letter (PDF)
May 28, 2008	SUPPL -9	View Letter (PDF)
Jun 12, 2006	SUPPL -7	View Letter (PDF)
Nov 8, 2004	SUPPL -5	View Letter (PDF)
Sep 29, 2004	SUPPL -6	View Letter (PDF)
Oct 17, 2003	SUPPL -2	View Letter (PDF)
Jan 5, 2001	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — 500MG

0 patents0 exclusivities▴

SUPPOSITORY;RECTAL | Approved: Jan 5, 2001

No patent or exclusivity listings for this strength.

#002 — 1GM

RLDAB

2 patents0 exclusivities▾

SUPPOSITORY;RECTAL | Approved: Nov 5, 2004